Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Core Insights - Vaxcyte, Inc. is set to present topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine, aimed at preventing invasive pneumococcal disease in adults aged 50 and older [1] Company Overview - Vaxcyte is focused on engineering high-fidelity vaccines to combat bacterial diseases, developing broad-spectrum conjugate and novel protein vaccines [3] - The lead candidate, VAX-24, is a Phase 3-ready 24-valent PCV, while VAX-31 is the broadest-spectrum PCV candidate currently in clinical trials [3] - Both VAX-24 and VAX-31 aim to improve upon existing PCVs by covering serotypes linked to high case-fatality rates and antibiotic resistance [3] Technology and Innovation - The company utilizes modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, to produce complex vaccines more efficiently [4] - This innovative approach is designed to enhance the immunological benefits of the vaccines [4] Pipeline Candidates - Vaxcyte's pipeline includes several vaccine candidates: - VAX-A1 for preventing Group A Strep infections - VAX-PG for slowing or stopping periodontal disease progression - VAX-GI for preventing Shigella [4]